Please assess the completion status of the following clinical trial:

Trial Title: Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months or more since cardiac transplant~* Clinically stable from a transplant perspective~* Maintained on a stable immunosuppressant regimen containing cyclosporine + an antiproliferative agent (e.g., azathioprine, mycophenolate), +/- an oral steroid~* Hypertension, as defined by a seated average systolic blood pressure of ≥ 140 mm Hg and a seated average diastolic blood pressure of ≥ 90 mm Hg, based on 3 separate measurements, spaced 2 minutes apart.~Exclusion Criteria:~* Clinical instability from a cardiac transplant perspective~* Contraindications to aliskiren therapy~* Conditions that may increase the risk of aliskiren adverse effects~* Severe hypertension~* Concomitant medications known to increase or decrease aliskiren plasma exposure.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows

Based on this trial design, predict the completion outcome and termination type (if applicable).